Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by MDD: processing speed, attention, visual learning, working memory, visual motor function and executive function.
The construct validity of each test for cognitive impairment in MDD as well as the sensitivity of these test to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.
The Detection Test uses a simple reaction time paradigm to measure processing speed.
Cognitive Domain Measured: Psychomotor Function
The Identification Test uses a choice reaction time paradigm to measure attention.
Cognitive Domain Measured: Attention
One Card Learning Test
The One Card Learning Test uses a pattern separation paradigm to measure visual memory.
Cognitive Domain Measured: Visual Learning
One Back Test
The One Back Test uses an n-back paradigm to measure working memory.
Cognitive Domain Measured: Working Memory
Groton Maze Learning Test
The Groton Maze Learning Test uses a maze learning paradigm to measure executive function.
Cognitive Domain Measured: Executive Function
|Length:||Between 5-20 minutes
(depending on the number of tests included in the battery*)
|Data Processing and Scoring:||Automated|
|Culture and Language Neutral:||Yes|
McIntyre, R. S., Lophaven, S., Olsen, C. K. (2014). A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology, 17(10), 1557-1567. doi: 10.1017/S1461145714000546.
Olver, J. S., Ignatiadis, S., Maruff, P., Burrows, G. D., and Norman, T. R., (2008) Quetiapine augmentation in depressed patients with partial response to antidepressants. Human Psychopharmacology Clinical and Experimental; 23: 653–660.
Shiroma, P.R., Albott, C.S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014). Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology, 17(11), 1805-1813. doi: 10.1017/S1461145714001011
Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., … Hashimoto, K. (2012). Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One, 7(8). doi: 10.1371/journal.pone.0042676